Abstract
The authors studied the effects of recombinant interferons (IFN), doxorubicin, and cisplatin against three cell lines derived from human epidermoid cervical carcinomas. These lines were SW 756, containing the genome of human papillomavirus (HPV) type 18, and CaSki and SiHa, containing HPV type 16. IFN-gamma suppressed the growth of all three lines, with a plateau in inhibitory effect beyond a concentration of 1000 units/ml. IFN-alpha was effective in this regard only against SW 756. In this line, the two IFNs together inhibited cell replication to a greater extent than the maximal effect of either IFN alone. Doxorubicin exerted a dose-dependent cytotoxic effect against all the lines, while cisplatin exhibited cytotoxicity only against SW 756. Doxorubicin and IFN-gamma, when used together, acted synergistically against CaSki and SiHa, and in an additive manner against SW 756.
References
Jan 1, 1979·Annals of the New York Academy of Sciences·G Sonnenfeld, T C Merigan
Mar 7, 1985·Nature·E SchwarzH zur Hausen
Sep 1, 1985·Virology·M M Pater, A Pater
Jan 1, 1986·American Journal of Obstetrics and Gynecology·W D LancasterA B Jenson
Feb 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S Vadhan-RajS E Krown
Jul 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R KurzrockJ U Gutterman
Apr 1, 1985·American Journal of Clinical Oncology·H B MussD R White
Aug 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P BonomiF J Major
Sep 15, 1985·American Journal of Obstetrics and Gynecology·S A GallK Trofatter
Jan 1, 1985·Cancer Immunology, Immunotherapy : CII·K A FoonR B Herberman
Nov 1, 1985·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J R QuesadaJ U Gutterman
Aug 1, 1970·Proceedings of the National Academy of Sciences of the United States of America·I GresserA Macieira-Coelho
Jul 15, 1973·International Journal of Cancer. Journal International Du Cancer·D Brouty-BoyéI Gresser
Feb 1, 1971·The Journal of Cell Biology·A Macieira-CoelhoI Gresser
May 9, 1981·Lancet·D IkićE Soos
Jan 1, 1981·Journal of Cancer Research and Clinical Oncology·D IkićD Jusić
Jan 1, 1981·Cancer Chemotherapy and Pharmacology·L B Epstein, S G Marcus
Mar 1, 1982·Cancer Letters·E De ClercqK Huygen
Sep 1, 1983·The Annals of Otology, Rhinology, and Laryngology·R B SessionsJ U Gutterman
Oct 1, 1983·Gynecologic Oncology·M FriedlanderP Russell
Dec 1, 1983·Gynecologic Oncology·A N DaghestaniJ L Lewis
Sep 4, 1980·Nature·D R LowyP M Howley
Sep 17, 1983·British Medical Journal·D J McCanceA Singer
Jan 1, 1984·Journal of Interferon Research·M Ito
Sep 12, 1957·Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character·A ISAACS, J LINDENMANN
Jun 1, 1962·Virology·K PAUCKERW HENLE
Citations
Jan 1, 1991·Cancer Immunology, Immunotherapy : CII·L S MassadJ L Collins
Dec 1, 1991·Journal of Dermatological Science·Y MaruguchiS Imamura
Dec 31, 1997·British Journal of Obstetrics and Gynaecology·B C SheuS C Huang
May 22, 2013·PloS One·Verena K CapelliniAndréa C Celotto
Dec 1, 1990·American Journal of Obstetrics and Gynecology·D G MutchJ L Collins
Oct 1, 1991·Cancer Letters·Y MaruguchiY Watanabe
Jul 27, 2005·Molecular Carcinogenesis·Manickam VenkatramanDevarajan Karunagaran
Mar 17, 2015·Molecular and Cellular Biochemistry·Swati Sood, Radhika Srinivasan